On Thursday 13 June, the European Commission announced that it had sent objections to Alchem International Pvt. Ltd. and its subsidiary Alchem International (H.K.) Limited, which it suspects, on a preliminary basis, of having engaged in a long-term agreement concerning an important pharmaceutical product.
Alchem manufactures, among other things, the pharmaceutical ingredient Scopolamine N-Butylbromide/Hyoscine (SNBB), an important ingredient in the production of the antispasmodic abdominal...